Safety—all treatment arms
ADVERSE EVENTS
Treatment-related AEs occurred in 35 of 62 (56.5%), 62 of 62 (100%), and 53 of 57 patients (93.0%) receiving pembrolizumab, pembrolizumab plus chemotherapy and chemotherapy, respectively (Treatment-related adverse events
